|
2
|
Wittmann D, Mehta A, Northouse L, Dunn R, Braun T, Duby A, An L, Arab L, Bangs R, Bober S, Brandon J, Coward M, Dunn M, Galbraith M, Garcia M, Giblin J, Glode M, Koontz B, Lowe A, Mitchell S, Mulhall J, Nelson C, Paich K, Saigal C, Skolarus T, Stanford J, Walsh T, Pollack CE. TrueNTH sexual recovery study protocol: a multi-institutional collaborative approach to developing and testing a web-based intervention for couples coping with the side-effects of prostate cancer treatment in a randomized controlled trial. BMC Cancer 2017; 17:664. [PMID: 28969611 PMCID: PMC5625773 DOI: 10.1186/s12885-017-3652-3] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Accepted: 09/22/2017] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Over half of men who receive treatment for prostate suffer from a range of sexual problems that affect negatively their sexual health, sexual intimacy with their partners and their quality of life. In clinical practice, however, care for the sexual side effects of treatment is often suboptimal or unavailable. The goal of the current study is to test a web-based intervention to support the recovery of sexual intimacy of prostate cancer survivors and their partners after treatment. METHODS The study team developed an interactive, web-based intervention, tailored to type of treatment received, relationship status (partnered/non-partnered) and sexual orientation. It consists of 10 modules, six follow the trajectory of the illness and four are theme based. They address sexual side effects, rehabilitation, psychological impacts and coaching for self-efficacy. Each includes a video to engage participants, psychoeducation and activities completed by participants on the web. Tailored strategies for identified concerns are sent by email after each module. Six of these modules will be tested in a randomized controlled trial and compared to usual care. Men with localized prostate cancer with partners will be recruited from five academic medical centers. These couples (N = 140) will be assessed prior to treatment, then 3 months and 6 months after treatment. The primary outcome will be the survivors' and partners' Global Satisfaction with Sex Life, assessed by a Patient Reported Outcome Measure Information Systems (PROMIS) measure. Secondary outcomes will include interest in sex, sexual activity, use of sexual aids, dyadic coping, knowledge about sexual recovery, grief about the loss of sexual function, and quality of life. The impact of the intervention on the couple will be assessed using the Actor-Partner Interaction Model, a mixed-effects linear regression model able to estimate both the association of partner characteristics with partner and patient outcomes and the association of patient characteristics with both outcomes. DISCUSSION The web-based tool represents a novel approach to addressing the sexual health needs of prostate cancer survivors and their partners that-if found efficacious-will improve access to much needed specialty care in prostate cancer survivorship. TRIAL REGISTRATION Clinicaltrials.gov registration # NCT02702453 , registered on March 3, 2016.
Collapse
Affiliation(s)
- D Wittmann
- University of Michigan, 2800 Plymouth Road, Bldg. 16, Rm 110E, Ann Arbor, MI, 48109-2800, USA.
| | - A Mehta
- Emory University, Atlanta, GA, USA
| | - L Northouse
- University of Michigan, 2800 Plymouth Road, Bldg. 16, Rm 110E, Ann Arbor, MI, 48109-2800, USA
| | - R Dunn
- University of Michigan, 2800 Plymouth Road, Bldg. 16, Rm 110E, Ann Arbor, MI, 48109-2800, USA
| | - T Braun
- University of Michigan, 2800 Plymouth Road, Bldg. 16, Rm 110E, Ann Arbor, MI, 48109-2800, USA
| | - A Duby
- University of Michigan, 2800 Plymouth Road, Bldg. 16, Rm 110E, Ann Arbor, MI, 48109-2800, USA
| | - L An
- University of Michigan, 2800 Plymouth Road, Bldg. 16, Rm 110E, Ann Arbor, MI, 48109-2800, USA
| | - L Arab
- University of California-Los Angeles, California, Los Angeles, USA
| | - R Bangs
- University of Michigan, 2800 Plymouth Road, Bldg. 16, Rm 110E, Ann Arbor, MI, 48109-2800, USA
| | - S Bober
- Dana Farber Cancer Center and Harvard University, Boston, MA, USA
| | - J Brandon
- University of Michigan, 2800 Plymouth Road, Bldg. 16, Rm 110E, Ann Arbor, MI, 48109-2800, USA
| | - M Coward
- University of North Carolina, Chapel Hill, NC, USA
| | - M Dunn
- University of North Carolina, Chapel Hill, NC, USA
| | - M Galbraith
- University of Colorado-Denver, Denver, CO, USA
| | - M Garcia
- University of California-San Francisco, San Francisco, CA, USA
| | - J Giblin
- Emory University, Atlanta, GA, USA
| | - M Glode
- University of Colorado-Denver, Denver, CO, USA
| | - B Koontz
- Duke University, Durham, NC, USA
| | - A Lowe
- Prostate Cancer Foundation-Australia, St Leonards, Australia
| | - S Mitchell
- University of Michigan, 2800 Plymouth Road, Bldg. 16, Rm 110E, Ann Arbor, MI, 48109-2800, USA
| | - J Mulhall
- Memorial Sloan Kettering Cancer Center, New York City, NY, USA
| | - C Nelson
- Memorial Sloan Kettering Cancer Center, New York City, NY, USA
| | - K Paich
- TrueNTH Movember Foundation, Michigan, USA
| | - C Saigal
- University of California-Los Angeles, California, Los Angeles, USA
| | - T Skolarus
- University of Michigan, 2800 Plymouth Road, Bldg. 16, Rm 110E, Ann Arbor, MI, 48109-2800, USA
- VA Ann Arbor Healthcare System, HSRD Center for Clinical Management Research, Ann Arbor, USA
| | - J Stanford
- Fred Hutchinson Comprehensive Cancer Center, Seattle, Washington, USA
- University of Washington, Seattle, Washington, USA
| | - T Walsh
- University of Washington, Seattle, Washington, USA
| | - C E Pollack
- Johns Hopkins University, Baltimore, MD, USA
| |
Collapse
|